AIMM Therapeutics BV is an Amsterdam based biotech company that develops human monoclonal antibodies for the treatment of cancer and infectious disease. AIMM was established ten years ago on the belief that scientists could harness the power of specific immune cells to develop clinically relevant antibody therapies while avoiding the inefficiencies inherent to other techniques. Today this proprietary platform technology is well validated as evidenced by the two AIMM antibodies now in human clinical trials and the deep pipeline that AIMM is currently advancing in cancer and infectious diseases.